稻米来源重组人血清白蛋白作为失代偿期肝硬化患者人血浆替代方案:一项随机、双盲、阳性对照、非劣效性试验
这项多中心、随机、双盲、阳性对照研究纳入中国22个中心失代偿期肝硬化且血清白蛋白≤30 g/L的患者,按4:1随机接受稻米来源重组人血清白蛋白(OsrHSA)或血浆来源人血清白蛋白(pHSA)静脉注射,主要结局为血清白蛋白达到35 g/L的比例。OsrHSA组130/171(76%)非劣效于pHSA组34/45(75.6%),差值0.5%,97.5%CI下限-0.119;所有次要结局无显著差异,无药物相关严重不良事件。
要点
- OsrHSA组血清白蛋白达标率76%(130/171),pHSA组75.6%(34/45),非劣效成立。
- 两组所有次要结局均无显著差异,未发生药物相关严重不良事件。
- 作者结论认为稻米来源HSA在有效性和安全性上非劣效于血浆来源HSA,但需3期试验确认。
核心结论
- 稻米来源重组人血清白蛋白在有效性和安全性上非劣效于血浆来源人血清白蛋白。
- 作者认为该发现需在3期试验中确认。
研究设计与样本
- 多中心、随机、双盲、阳性对照研究,患者来自中国22个中心。
- 纳入失代偿期肝硬化且血清白蛋白≤30 g/L的患者,按4:1随机分配至OsrHSA组或pHSA组。
- 给药方式为每日一次静脉注射10 g或20 g,直至血清白蛋白达到35 g/L,最长2周,随访2周。
- 主要结局为血清白蛋白达到35 g/L的患者比例,非劣效界值<-0.20。
- 在意向接受研究药物且至少有一次基线后血清白蛋白值的患者(全分析集,FAS)中评估结局;安全性在所有接受研究药物的患者中评估。
主要发现
- 2021年3月22日至2022年6月2日期间,220例患者接受OsrHSA(n=175)或pHSA(n=45)。
- FAS纳入216例患者(OsrHSA组n=171;pHSA组n=45)。
- OsrHSA组主要结局为130/171(76%),pHSA组为34/45(75.6%),差值0.5%,97.5%CI下限-0.119。
- OsrHSA与pHSA的所有次要结局之间无显著差异。
- 未发生药物相关严重不良事件。
关键数值与推荐
- 非劣效界值为<-0.20。
- 主要结局达标率:OsrHSA组130/171(76%)vs pHSA组34/45(75.6%),差值0.5%,97.5%CI下限-0.119。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者结论指出该发现需在3期试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite inadequate supply and potential contamination risk, human plasma has remained the only source for human serum albumin (pHSA) intravenous administration since the 1940s. OBJECTIVE: We sought to establish the safety and efficacy of OsrHSA, a recombinant HSA from bioengineered Oryza sativa (rice). DESIGN: In this multicentre, randomised, double-blind and positive-controlled study, patients with decompensated liver cirrhosis and serum albumin ≤30 g/L were recruited from 22 centres in China. The patients were randomly assigned to OsrHSA or pHSA (4:1) to once-daily intravenous injection (10 g or 20 g) until their serum albumin level reached 35 g/L, for a maximum of 2 weeks, with 2 weeks of follow-up. The primary outcome was the proportion of patients to reach a serum albumin level of 35 g/L (non-inferiority margin <-0.20). Outcomes were evaluated in patients who received the study drug and had at least one post-baseline serum albumin value (full analysis set, FAS). Safety was evaluated in all patients who received the study drug. RESULTS: Between 22 March 2021 and 2 June 2022, 220 patients received OsrHSA (n=175) or pHSA (n=45). 216 patients were included in the FAS (OsrHSA, n=171; pHSA, n=45). Primary outcome of OsrHSA (130/171, 76%) was non-inferior to pHSA (34/45, 75.6%) (difference=0.5%; lower limit of 97.5% CI=-0.119). There was no significant difference between all secondary outcomes of OsrHSA and pHSA. There were no drug-related serious adverse events. CONCLUSIONS: Rice-derived HSA is non-inferior to plasma-derived HSA in efficacy and safety. This finding should be confirmed in phase 3 trial. TRIAL REGISTRATION NUMBER: NCT04835480.
引用
- Niu J, Gao Y, Wang G, et al. Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial. Gut. 2025. PMID: 40555465. doi:10.1136/gutjnl-2025-335577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。